{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T19:15:18Z","timestamp":1775243718762,"version":"3.50.1"},"reference-count":34,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T00:00:00Z","timestamp":1679875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Objective: To present clinical findings and multimodal imaging of three patients who developed bacillary layer detachments (BALADs) shortly after half-fluence, half-dose (HFHD) verteporfin photodynamic therapy (PDT). Methods: Retrospective observational case series. Three patients were treated with HFHD-PDT for (1) macular neovascularisation five years after resolved central serous chorioretinopathy (CSC), (2) persistent serous retinal detachment (SRD) from chronic CSC, and (3) neovascular age-related macular degeneration with persistent SRD despite intravitreal anti-VEGF therapy. Results: Each patient developed a BALAD after HFHD-PDT. Acute fulminant exudation caused subretinal fluid expansion into the inner photoreceptor layer, cleaving myoid from ellipsoid zones in the central macula. Subretinal fluid and the BALADs subsequently resolved over 6\u20138 weeks. Conclusions: The subretinal fluid and BALAD following HFHD-PDT were transient and did not cause photoreceptor damage over a 6-month follow-up period. We speculate that the reduced-impact HFHD protocol decreases direct tissue damage but increases proinflammatory cytokines. The long-term pathophysiological consequences of the resolved BALADs are unknown.<\/jats:p>","DOI":"10.3390\/ph16040494","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T03:31:48Z","timestamp":1679887908000},"page":"494","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Half-Fluence, Half-Dose Photodynamic Therapy: Less Direct Damage but More Inflammation?"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8681-0159","authenticated-orcid":false,"given":"Thomas","family":"Desmettre","sequence":"first","affiliation":[{"name":"Centre de R\u00e9tine M\u00e9dicale, 187 rue de Menin, 59520 Marquette-Lez-Lille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin A.","family":"Mainster","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Kansas School of Medicine, Prairie Village, KS 66208, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerardo","family":"Ledesma-Gil","sequence":"additional","affiliation":[{"name":"Retina Department, Institute of Ophthalmology, Fundaci\u00f3n Conde de Valenciana, Mexico City 06800, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1751-1097.1992.tb04222.x","article-title":"How does photodynamic therapy work?","volume":"55","author":"Henderson","year":"1992","journal-title":"Photochem. Photobiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/jnci\/90.12.889","article-title":"Photodynamic therapy","volume":"90","author":"Dougherty","year":"1998","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1097\/IAE.0b013e3181b1bb1a","article-title":"Anti-VEGF drugs as the 2009 first-line therapy for choroidal neovascularization in pathologic myopia","volume":"29","author":"Cohen","year":"2009","journal-title":"Retina"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1517\/17425255.2012.701617","article-title":"Evaluation of verteporfin pharmakokinetics--redefining the need of photosensitizers in ophthalmology","volume":"8","author":"Ziemssen","year":"2012","journal-title":"Expert. Opin. Drug. Metab. Toxicol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Finger, R.P., Daien, V., Eldem, B.M., Talks, J.S., Korobelnik, J.-F., Mitchell, P., Sakamoto, T., Wong, T.Y., Pantiri, K., and Carrasco, J. (2020). Anti-vascular endothelial growth factor in neovascular age-related macular degeneration\u2014A systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems. BMC Ophthalmol., 20.","DOI":"10.1186\/s12886-020-01554-2"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40123-020-00250-0","article-title":"Photodynamic Therapy for Chorioretinal Diseases: A Practical Approach","volume":"9","author":"Subhi","year":"2020","journal-title":"Ophthalmol. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.3892\/etm.2016.3886","article-title":"Effect of anti-VEGF drugs combined with photodynamic therapy in the treatment of age-related macular degeneration","volume":"12","author":"Dong","year":"2016","journal-title":"Exp. Ther. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.1167\/iovs.17-23747","article-title":"Anti-VEGF Monotherapy Versus Photodynamic Therapy and Anti-VEGF Combination Treatment for Neovascular Age-Related Macular Degeneration: A Meta-Analysis","volume":"59","author":"Gao","year":"2018","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/IAE.0b013e31823f99a9","article-title":"Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: A pilot study","volume":"32","author":"Yannuzzi","year":"2012","journal-title":"Retina"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"100770","DOI":"10.1016\/j.preteyeres.2019.07.003","article-title":"Central serous chorioretinopathy: Towards an evidence-based treatment guideline","volume":"73","author":"Yzer","year":"2019","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Iacono, P., Da Pozzo, S., Varano, M., and Parravano, M. (2020). Photodynamic Therapy with Verteporfin for Chronic Central Serous Chorioretinopathy: A Review of Data and Efficacy. Pharmaceuticals, 13.","DOI":"10.3390\/ph13110349"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/eye.2013.13","article-title":"Efficacy of half-fluence photodynamic therapy depending on the degree of choroidal hyperpermeability in chronic central serous chorioretinopathy","volume":"27","author":"Lim","year":"2013","journal-title":"Eye"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1089\/jop.2013.0169","article-title":"Half-dose verteporfin combined with half-fluence photodynamic therapy for chronic central serous chorioretinopathy","volume":"30","author":"Liu","year":"2014","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e1522","DOI":"10.1111\/aos.15148","article-title":"Clinical impact of the worldwide shortage of verteporfin (Visudyne\u00ae) on ophthalmic care","volume":"100","author":"Sirks","year":"2022","journal-title":"Acta Ophthalmol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.3928\/15428877-20101031-10","article-title":"Acute severe visual decrease after photodynamic therapy with verteporfin: Spectral-domain OCT features","volume":"41","author":"Keane","year":"2010","journal-title":"Ophthalmic Surg. Lasers Imaging"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/j.jcjo.2016.08.001","article-title":"Atypical transient subretinal exudation following photodynamic therapy for chronic central serous retinopathy: A case report","volume":"52","author":"Mandelcorn","year":"2017","journal-title":"Can. J. Ophthalmol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.jcjo.2017.06.005","article-title":"Response to \u201cExudative complications following photodynamic therapy\u201d","volume":"52","author":"Somani","year":"2017","journal-title":"Can. J. Ophthalmol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Ledesma-Gil, G., Desmettre, T., and Mainster, M.A. (2021). Bacillary Layer Detachment after Photodynamic Therapy for Central Serous Chorioretinopathy. Retin. Cases Brief. Rep.","DOI":"10.1097\/ICB.0000000000001190"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/IAE.0000000000003404","article-title":"Acute Exudative Maculopathy and Bacillary Layer Detachment in Patients with Central Serous Chorioretinopathy after Photodynamic Therapy","volume":"42","year":"2022","journal-title":"Retina"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/ICB.0000000000000356","article-title":"Incidence of Acute Exudative Maculopathy after Reduced-Fluence Photodynamic Therapy","volume":"11","author":"Mammo","year":"2017","journal-title":"Retin. Cases Brief. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/IAE.0000000000002343","article-title":"Photodynamic therapy-induced acute exudative maculopathy: Incidence, clinical features and long-term outcomes","volume":"40","author":"Manayath","year":"2020","journal-title":"Retina"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Kim, M.H., Chung, Y.R., and Song, J.H. (2021). Transient accumulation of subretinal fluid after half-fluence photodynamic therapy in neovascular age-related macular degeneration. BMC Ophthalmol., 21.","DOI":"10.1186\/s12886-021-01867-w"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.ajo.2005.04.041","article-title":"Transient serous retinal detachment in classic and occult choroidal neovascularization after photodynamic therapy","volume":"140","author":"Mennel","year":"2005","journal-title":"Am. J. Ophthalmol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jcjo.2017.05.013","article-title":"Exudative complications following photodynamic therapy","volume":"52","author":"Ranjan","year":"2017","journal-title":"Can. J. Ophthalmol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.oret.2019.12.003","article-title":"The Bacillary Detachment in Posterior Segment Ocular Diseases","volume":"4","author":"Cicinelli","year":"2020","journal-title":"Ophthalmol. Retina"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/ICB.0000000000000817","article-title":"Presumed foveal bacillary layer detachment in a patient with toxoplasmosis chorioretinitis and pachychoroid disease","volume":"15","author":"Mehta","year":"2021","journal-title":"Retin. Cases Brief. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1097\/IAE.0000000000003217","article-title":"Bacillary layer detachment: Multimodal imaging and histologic evidence of a novel optical coherence tomography terminology","volume":"41","author":"Ramtohul","year":"2021","journal-title":"Retina"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1076\/ceyr.16.2.83.5088","article-title":"Localization of lipoprotein-delivered benzoporphyrin derivative in the rabbit eye","volume":"16","author":"Haimovici","year":"1997","journal-title":"Curr. Eye Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1136\/bjo.2007.121830","article-title":"Histopathological findings in postmortem eyes after photodynamic therapy for choroidal neovascularisation in age-related macular degeneration: Report of two cases","volume":"91","author":"Kang","year":"2007","journal-title":"Br. J. Ophthalmol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1001\/archopht.1995.01100060136048","article-title":"Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin","volume":"113","author":"Miller","year":"1995","journal-title":"Arch. Ophthalmol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0039-6257(00)00158-2","article-title":"Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration","volume":"45","author":"Hasan","year":"2000","journal-title":"Surv. Ophthalmol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1136\/bjo.85.9.1086","article-title":"Histological findings of surgically excised choroidal neovascular membranes after photodynamic therapy","volume":"85","author":"Schnurrbusch","year":"2001","journal-title":"Br. J. Ophthalmol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s00417-005-0237-7","article-title":"Effect of photodynamic therapy on the function of the outer blood-retinal barrier in an in vitro model","volume":"244","author":"Mennel","year":"2006","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/IAE.0000000000000331","article-title":"Pachychoroid neovasculopathy","volume":"35","author":"Pang","year":"2015","journal-title":"Retina"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/4\/494\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:03:45Z","timestamp":1760123025000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/4\/494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,27]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["ph16040494"],"URL":"https:\/\/doi.org\/10.3390\/ph16040494","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,27]]}}}